Journal of Clinical Investigation · 2023 · 47 citations · 34 references
MedicineBiochemistryOncologyMetabolic RegulationMolecular OncologySteroid BiochemistryCancer MetabolismCancer-associated FibroblastsMetabolic ReprogrammingMetabolic Reprogramming In CancerProstate CancerSteroidogenesis Regulation3 Alpha-hydroxysteroid Dehydrogenase3 Beta-hydroxysteroid Dehydrogenase3Beta-hydroxysteroid Dehydrogenase RegulationAndrogen Biosynthesis RegulationAndrogen Receptor ExpressionCancer-associated Fibroblast MetabolismCastration-resistant Prostate Cancer TherapyO-glcnacylation In Cancer
After androgen deprivation, prostate cancer frequently becomes castration resistant (CRPC), with intratumoral androgen production from extragonadal precursors that activate the androgen receptor pathway. 3β-Hydroxysteroid dehydrogenase-1 (3βHSD1) is the rate-limiting enzyme for extragonadal androgen synthesis, which together lead to CRPC. Here, we show that cancer-associated fibroblasts (CAFs) increased epithelial 3βHSD1 expression, induced androgen synthesis, activated the androgen receptor, and induced CRPC. Unbiased metabolomics revealed that CAF-secreted glucosamine specifically induced 3βHSD1. CAFs induced higher GlcNAcylation in cancer cells and elevated expression of the transcription factor Elk1, which induced higher 3βHSD1 expression and activity. Elk1 genetic ablation in cancer epithelial cells suppressed CAF-induced androgen biosynthesis in vivo. In patient samples, multiplex fluorescent imaging showed that tumor cells expressed more 3βHSD1 and Elk1 in CAF-enriched areas compared with CAF-deficient areas. Our findings suggest that CAF-secreted glucosamine increases GlcNAcylation in prostate cancer cells, promoting Elk1-induced HSD3B1 transcription, which upregulates de novo intratumoral androgen synthesis to overcome castration.
34
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +17
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James, Johann S. de Bono, Melissa Spears et al. · New England Journal of Medicine · 2017 · 1.8K citations · Full text
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida, Joanna Cyrta, Glenn Heller et al. · Proceedings of the National Academy of Sciences · 2019 · 1.4K citations · Full text
The Lancet · 2021 · 367 citations · Full text
Medicine, Oncology, Pharmacotherapy +17